Home › Trials › NCT07110454

Long-term follow-up of the Minder implanted EEG system for epilepsy care

A Prospective Long-Term Follow-Up Study to Evaluate the Use of the Minder Device to Aid in Treatment After Actionable Event Identification in Patients Diagnosed With Epilepsy.

Observational Epiminder America, Inc. · NCT07110454

This follow-up will see if long-term use of the implanted Minder sub‑scalp EEG system helps doctors manage care for people with epilepsy whose seizures are not well captured by standard EEGs.

Quick facts

Study typeObservational
Enrollment210 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorEpiminder America, Inc. Industry-sponsored
Locations11 sites (Phoenix, Arizona and 10 other locations)
Trial IDNCT07110454 on ClinicalTrials.gov

What this trial studies

This is an observational long‑term follow‑up of participants who previously received the implanted Minder sub‑scalp EEG device in the DETECT program. The study collects periodic information on general wellbeing, healthcare use, and participants' experience using Minder data after an actionable event or completion of the 6‑month DETECT visit. Participants remain under the care of their treating physicians while study staff document how Minder data are used in routine clinical decision‑making. The Minder System has FDA De Novo classification and is being followed in real‑world settings at participating centers.

Who should consider this trial

Good fit: Ideal candidates are people who enrolled in the DETECT program, received the implanted Minder device, completed DETECT by having an actionable event or the 6‑month visit, and still have the device implanted.

Not a fit: Patients who never received the Minder implant, who require MRI or other contraindicated procedures, or whose seizures are already well captured and controlled with standard monitoring are unlikely to benefit from this follow‑up.

Why it matters

Potential benefit: If successful, long‑term Minder monitoring could help clinicians detect events missed by standard EEG and guide treatment changes that reduce seizures and improve quality of life.

How similar studies have performed: Prior data from the DETECT program supported FDA De Novo clearance of the Minder system, but long‑term outpatient outcomes and real‑world use patterns are less well characterized.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participant met all inclusion criteria, was enrolled in the DETECT study, and received the Minder device
* Participant completed the DETECT study by receiving an actionable event or by completing the 6-month follow-up visit
* Participant continues to have the Minder device implanted
* Participant must continue to meet relevant DETECT study inclusion criteria

Exclusion Criteria:

* Participant meets any relevant DETECT study exclusion criteria including needing treatments or assessments that are not indicated with the Minder System like Magnetic Resonance Imaging (MRI)

Where this trial is running

Phoenix, Arizona and 10 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions EpilepsyMinder SystemSub-scalp EEG monitoring device
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.